Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082605 | 0.84 | KIT (0.41) | MAP2K7LMNAENPP1 | |
| SCHEMBL4082603 | 0.83 | KRAS (0.44) | MAP2K7AKT1ENPP1 | |
| SCHEMBL4086517 | 0.77 | MAP2K7 (0.57) | HTR2CMAP2K7AKT1CYP1A2CYP2C19 | |
| SCHEMBL13938401 | 0.77 | KIT (0.49) | LMNA | |
| SCHEMBL13961527 | 0.77 | KIT (0.49) | LMNA | |
| SCHEMBL14196555 | 0.77 | KIT (0.51) | LMNA | |
| SCHEMBL5123678 | 0.76 | LRRK2 (0.44) | HTR2CMAP2K7AKT1 | |
| SCHEMBL13938382 | 0.75 | KIT (0.51) | AKT1LMNA | |
| SCHEMBL14196197 | 0.75 | KIT (0.49) | LMNA | |
| SCHEMBL13938544 | 0.74 | KIT (0.57) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | HTR2C 3071/4885EPHX2 2510/4885MAP2K7 175/4885 |
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | CDK2, PACSIN2, AKT1 | HTR2C 2345/4885EPHX2 2458/4885MAP2K7 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.